NASDAQ:MRTX - Mirati Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $217.92
  • Forecasted Upside: 33.67 %
  • Number of Analysts: 16
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
▼ -2.04 (-1.24%)

This chart shows the closing price for MRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mirati Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRTX

Analyst Price Target is $217.92
▲ +33.67% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Mirati Therapeutics in the last 3 months. The average price target is $217.92, with a high forecast of $285.00 and a low forecast of $160.00. The average price target represents a 33.67% upside from the last price of $163.03.

This chart shows the closing price for MRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 16 contributing investment analysts is to buy stock in Mirati Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/4/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellUpgradeNeutral ➝ BuyLow
6/4/2021CitigroupUpgradeNeutral ➝ BuyLow
5/24/2021OppenheimerReiterated RatingOutperform ➝ Market Perform$245.00 ➝ $160.00Medium
5/17/2021OppenheimerDowngradeOutperform ➝ Market Perform$245.00 ➝ $160.00Low
5/10/2021HC WainwrightLower Price TargetBuy$255.00 ➝ $251.00Medium
5/10/2021Jefferies Financial GroupUpgradeHold ➝ Buy$208.00 ➝ $196.00Medium
3/1/2021OppenheimerLower Price TargetOutperform$260.00 ➝ $255.00Low
3/1/2021HC WainwrightLower Price TargetBuy$257.00 ➝ $255.00Low
1/15/2021HC WainwrightLower Price TargetBuy$265.00 ➝ $257.00Low
12/16/2020Credit Suisse GroupBoost Price TargetOutperform$225.00 ➝ $285.00Low
12/8/2020Evercore ISIInitiated CoverageOutperformMedium
12/8/2020JMP SecuritiesInitiated CoverageMarket PerformMedium
11/17/2020Bank of AmericaDowngradeNeutral ➝ Underperform$196.00Low
11/10/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$206.00 ➝ $208.00Low
11/10/2020GuggenheimDowngradeBuy ➝ Neutral$230.00Low
11/9/2020HC WainwrightBoost Price TargetBuy$233.00 ➝ $265.00Medium
11/5/2020OppenheimerBoost Price Target$225.00 ➝ $260.00Low
11/5/2020Piper SandlerBoost Price TargetOverweight$210.00 ➝ $260.00Medium
11/2/2020HC WainwrightLower Price TargetBuy$238.00 ➝ $233.00Low
10/29/2020BarclaysBoost Price TargetOverweight$143.00 ➝ $244.00High
10/27/2020Credit Suisse GroupBoost Price TargetOutperform$190.00 ➝ $225.00High
10/26/2020OppenheimerBoost Price TargetOutperform$190.00 ➝ $225.00High
10/26/2020SVB LeerinkBoost Price TargetOutperform$134.00 ➝ $195.00High
10/26/2020The Goldman Sachs GroupBoost Price TargetBuy$152.00 ➝ $267.00High
10/26/2020HC WainwrightBoost Price TargetBuy$222.00 ➝ $238.00High
10/26/2020Piper SandlerBoost Price TargetOverweight$170.00 ➝ $210.00High
10/21/2020BMO Capital MarketsBoost Price TargetMarket Perform$101.00 ➝ $176.00High
10/16/2020HC WainwrightBoost Price TargetBuy$185.00 ➝ $222.00High
10/8/2020CSFBBoost Price TargetOutperform$140.00 ➝ $190.00Medium
10/8/2020Credit Suisse GroupBoost Price TargetOutperform$140.00 ➝ $190.00Medium
9/28/2020Bank of AmericaInitiated CoverageNeutral$172.00Low
9/21/2020OppenheimerBoost Price TargetOutperform$133.00 ➝ $190.00Low
9/21/2020Piper SandlerBoost Price TargetOverweight$145.00 ➝ $170.00Low
9/18/2020CitigroupDowngradeBuy ➝ Neutral$127.00 ➝ $183.00Medium
9/17/2020HC WainwrightBoost Price TargetBuy$163.00 ➝ $185.00High
8/10/2020OppenheimerBoost Price Target$105.00 ➝ $133.00Medium
8/10/2020HC WainwrightReiterated RatingBuy$163.00Medium
8/7/2020Credit Suisse GroupBoost Price TargetOutperform$135.00 ➝ $140.00Medium
8/7/2020BarclaysBoost Price TargetOverweight$123.00 ➝ $143.00Medium
7/29/2020Credit Suisse GroupBoost Price TargetOutperform$115.00 ➝ $135.00Medium
5/1/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$116.00High
4/16/2020The Goldman Sachs GroupInitiated CoverageBuy$151.00High
3/30/2020OppenheimerLower Price TargetOutperform$129.00 ➝ $105.00High
3/12/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$88.00High
2/28/2020HC WainwrightReiterated RatingBuy$134.00 ➝ $126.00High
1/27/2020BMO Capital MarketsInitiated CoverageMarket Perform$101.00Low
1/24/2020HC WainwrightReiterated RatingBuy$117.00 ➝ $134.00Medium
1/7/2020CowenReiterated RatingBuyHigh
11/5/2019GuggenheimBoost Price TargetBuy$116.00 ➝ $128.00Low
10/29/2019Cantor FitzgeraldBoost Price TargetNeutral$81.00 ➝ $85.00High
10/18/2019CowenReiterated RatingBuyLow
10/17/2019HC WainwrightReiterated RatingBuyHigh
10/9/2019CitigroupSet Price TargetBuy$130.00Low
9/27/2019Credit Suisse GroupSet Price TargetPositive ➝ Buy$120.00 ➝ $115.00Low
9/24/2019GuggenheimUpgradeNeutral ➝ Buy$116.00High
9/11/2019B. RileyLower Price TargetNeutral$92.00 ➝ $83.00High
9/9/2019Cantor FitzgeraldLower Price TargetNeutral$85.00 ➝ $81.00High
9/9/2019Jefferies Financial GroupUpgradeHold ➝ Buy$89.00 ➝ $105.00Medium
8/6/2019HC WainwrightReiterated RatingBuy$117.00High
8/6/2019CowenReiterated RatingBuyHigh
8/2/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$101.00 ➝ $85.00High
7/31/2019SVB LeerinkSet Price TargetBuy$118.00High
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold ➝ Hold$86.00Medium
7/12/2019JPMorgan Chase & Co.Boost Price TargetNeutral$70.00 ➝ $101.00Low
6/19/2019B. RileyDowngradeBuy ➝ Neutral$60.00 ➝ $92.00Medium
6/7/2019GuggenheimDowngradeBuy ➝ Neutral$95.56Medium
6/5/2019HC WainwrightReiterated RatingBuy ➝ Buy$84.00 ➝ $117.00Low
6/5/2019BarclaysBoost Price TargetOverweight$85.00 ➝ $123.00Low
6/4/2019SunTrust BanksBoost Price TargetBuy$120.00Medium
6/4/2019Piper Jaffray CompaniesBoost Price TargetOverweight$85.00 ➝ $125.00Medium
6/4/2019CowenReiterated RatingBuyHigh
6/4/2019Cantor FitzgeraldBoost Price TargetNeutral ➝ Positive$66.00 ➝ $85.00High
6/4/2019CitigroupUpgradeNeutral ➝ Buy$76.00 ➝ $132.00High
5/16/2019Cantor FitzgeraldReiterated RatingHoldHigh
5/15/2019CowenReiterated RatingBuyHigh
5/1/2019Cantor FitzgeraldReiterated RatingHold$66.00High
4/17/2019JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$72.00High
4/2/2019Cantor FitzgeraldSet Price TargetHold$66.00Low
3/25/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$85.00Medium
3/19/2019OppenheimerReiterated RatingBuyMedium
3/13/2019CowenReiterated RatingBuyHigh
3/7/2019OppenheimerSet Price TargetBuy$81.00Low
3/4/2019Cantor FitzgeraldInitiated CoverageNeutral$66.00Medium
3/4/2019CitigroupBoost Price TargetBuy ➝ Neutral$64.00 ➝ $77.00Low
2/15/2019SVB LeerinkReiterated RatingOutperformHigh
2/15/2019HC WainwrightReiterated RatingBuyMedium
2/15/2019Piper Jaffray CompaniesInitiated CoverageOverweight$85.00Medium
1/16/2019OppenheimerBoost Price TargetOutperform$57.00 ➝ $65.00High
11/30/2018B. RileyInitiated CoverageBuy ➝ Buy$60.00Low
11/15/2018Jefferies Financial GroupReiterated RatingHold$37.00High
11/12/2018HC WainwrightReiterated RatingBuy$65.00High
11/11/2018OppenheimerSet Price TargetBuy$57.00Medium
10/30/2018OppenheimerSet Price TargetBuy$62.00Low
10/29/2018GuggenheimUpgradeNeutral ➝ BuyLow
10/22/2018CowenReiterated RatingBuyHigh
9/27/2018CowenReiterated RatingBuyHigh
9/17/2018GuggenheimInitiated CoverageNeutralLow
7/20/2018HC WainwrightBoost Price TargetBuy$63.00High
7/9/2018OppenheimerBoost Price TargetOutperform$35.00 ➝ $62.00High
7/5/2018CitigroupBoost Price TargetBuy$37.00 ➝ $64.00Medium
6/28/2018CowenReiterated RatingBuyMedium
6/19/2018SunTrust BanksBoost Price TargetBuy$60.00Medium
3/12/2018HC WainwrightBoost Price TargetBuy$40.00High
3/12/2018BarclaysInitiated CoverageOverweight$44.00High
3/9/2018SunTrust BanksBoost Price TargetPositive ➝ Buy$40.00High
3/5/2018CitigroupBoost Price TargetBuy ➝ Buy$23.00 ➝ $37.00High
1/9/2018HC WainwrightBoost Price TargetBuy ➝ Buy$17.00 ➝ $21.00N/A
1/8/2018OppenheimerSet Price TargetBuy$18.00High
12/21/2017CowenInitiated CoverageOutperformLow
11/22/2017OppenheimerReiterated RatingBuy$18.00N/A
11/14/2017HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $17.00N/A
11/14/2017SVB LeerinkUpgradeMarket Perform ➝ Outperform$9.00N/A
11/7/2017HC WainwrightReiterated RatingBuyN/A
10/12/2017SunTrust BanksReiterated RatingBuy$13.00N/A
10/12/2017HC WainwrightReiterated RatingBuy ➝ Buy$20.00N/A
10/2/2017SunTrust BanksReiterated RatingBuy$13.00High
9/19/2017CIBCInitiated CoverageOutperform ➝ Outperform$18.00Low
9/19/2017CitigroupReiterated RatingBuy$8.00 ➝ $16.00Low
9/18/2017OppenheimerInitiated CoverageOutperform$18.00Medium
9/15/2017SVB LeerinkBoost Price TargetMkt Perform ➝ Market Perform$7.00 ➝ $9.00N/A
8/4/2017Jefferies Financial GroupSet Price TargetHold$5.00Low
6/12/2017Jefferies Financial GroupReiterated RatingHold$4.50Medium
4/12/2017Jefferies Financial GroupReiterated RatingHold$5.50High
3/11/2017HC WainwrightSet Price TargetBuy$12.00 ➝ $10.00N/A
3/11/2017Jefferies Financial GroupReiterated RatingHold$5.00 ➝ $5.50N/A
1/9/2017Jefferies Financial GroupReiterated RatingHold$5.00N/A
11/18/2016Avondale PartnersDowngradeOutperform ➝ Market PerformN/A
11/17/2016HC WainwrightInitiated CoverageBuy$12.00N/A
11/11/2016SVB LeerinkReiterated RatingHold$7.00N/A
11/4/2016WedbushReiterated RatingOutperform$12.00N/A
10/4/2016WedbushReiterated RatingOutperform$12.00N/A
8/19/2016Piper Jaffray CompaniesReiterated RatingNeutralN/A
8/18/2016Piper Jaffray CompaniesSet Price TargetHold$7.00N/A
8/8/2016Piper Jaffray CompaniesReiterated RatingNeutral$14.00 ➝ $7.00N/A
(Data available from 6/23/2016 forward)
Mirati Therapeutics logo
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $163.03
Low: $161.73
High: $166.73

50 Day Range

MA: $158.70
Low: $144.00
High: $172.04

52 Week Range

Now: $163.03
Low: $110.17
High: $249.42


381,494 shs

Average Volume

474,691 shs

Market Capitalization

$8.39 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Mirati Therapeutics?

The following Wall Street analysts have issued research reports on Mirati Therapeutics in the last twelve months: Bank of America Co., Barclays PLC, BMO Capital Markets, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Credit Suisse Group AG, CSFB, Evercore ISI, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Oppenheimer Holdings Inc., Piper Sandler, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for MRTX.

What is the current price target for Mirati Therapeutics?

13 Wall Street analysts have set twelve-month price targets for Mirati Therapeutics in the last year. Their average twelve-month price target is $217.92, suggesting a possible upside of 32.0%. Credit Suisse Group AG has the highest price target set, predicting MRTX will reach $285.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $160.00 for Mirati Therapeutics in the next year.
View the latest price targets for MRTX.

What is the current consensus analyst rating for Mirati Therapeutics?

Mirati Therapeutics currently has 1 sell rating, 4 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRTX will outperform the market and that investors should add to their positions of Mirati Therapeutics.
View the latest ratings for MRTX.

What other companies compete with Mirati Therapeutics?

How do I contact Mirati Therapeutics' investor relations team?

Mirati Therapeutics' physical mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is 858-332-3410 and its investor relations email address is [email protected] The official website for Mirati Therapeutics is